HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Lin Gui Selected Research

Guanosine Diphosphate (GDP)

11/2019Upfront radiation is essential for high-risk early-stage extranodal NK/T-cell lymphoma, nasal type: comparison of two sequential treatment modalities combining radiotherapy and GDP (gemcitabine, dexamethasone, and cisplatin) in the modern era.
1/2018Phase 2 Study of First-line Intensity Modulated Radiation Therapy Followed by Gemcitabine, Dexamethasone, and Cisplatin for High-Risk, Early Stage Extranodal Nasal-Type NK/T-Cell Lymphoma: The GREEN Study.
9/2017Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type.
2/2017Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma-not otherwise specified.
10/2016Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas.
2/2016GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type.
3/2013Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Lin Gui Research Topics

Disease

32Neoplasms (Cancer)
05/2022 - 01/2005
13Lymphoma (Lymphomas)
09/2021 - 06/2012
8Thrombosis (Thrombus)
01/2019 - 07/2010
7Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse)
05/2022 - 02/2015
6Neoplasm Metastasis (Metastasis)
03/2022 - 09/2015
6Neutropenia
01/2018 - 10/2009
5Peripheral T-Cell Lymphoma (Lymphoma, T Cell, Peripheral)
10/2021 - 03/2013
5Thrombocytopenia (Thrombopenia)
01/2018 - 10/2009
4Inflammation (Inflammations)
01/2018 - 01/2017
4Non-Hodgkin Lymphoma (Lymphosarcoma)
10/2017 - 10/2009
4Autoimmune Diseases (Autoimmune Disease)
01/2016 - 05/2013
3T-Cell Lymphoma (Lymphoma, T Cell)
07/2022 - 01/2018
3Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
12/2020 - 04/2010
3Nasopharyngeal Carcinoma
01/2020 - 08/2015
3Anemia
01/2018 - 02/2016
2Extranodal NK-T-Cell Lymphoma
09/2022 - 11/2019
2Anaplastic Large-Cell Lymphoma (Ki 1 Lymphoma)
07/2022 - 02/2015
2Wounds and Injuries (Trauma)
05/2022 - 07/2013
2Disease Progression
04/2022 - 01/2020
2Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular)
06/2021 - 01/2021
2Lymphatic Metastasis
01/2020 - 04/2018
2Carcinogenesis
04/2018 - 09/2016
2Venous Thrombosis (Deep-Vein Thrombosis)
01/2018 - 01/2018
2B-Cell Lymphoma (Lymphoma, B Cell)
09/2015 - 02/2015
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/2013 - 03/2013
1Genetic Predisposition to Disease (Genetic Predisposition)
06/2022
1Bacterial Infections (Bacterial Infection)
05/2022
1Bone Neoplasms (Bone Cancer)
03/2022
1Breast Neoplasms (Breast Cancer)
04/2021
1Anaplastic Thyroid Carcinoma
01/2021
1Carcinoma (Carcinomatosis)
01/2021
1Hypercalcemia (Milk Alkali Syndrome)
12/2020
1Myelodysplastic Syndromes (Myelodysplastic Syndrome)
10/2020

Drug/Important Bio-Agent (IBA)

8GemcitabineFDA Link
11/2019 - 03/2013
7Rituximab (Mabthera)FDA Link
05/2022 - 09/2015
7Guanosine Diphosphate (GDP)IBA
11/2019 - 03/2013
6Cisplatin (Platino)FDA LinkGeneric
11/2019 - 09/2015
6Dexamethasone (Maxidex)FDA LinkGeneric
11/2019 - 07/2015
5Proteins (Proteins, Gene)FDA Link
05/2022 - 07/2009
5P-SelectinIBA
01/2018 - 01/2017
4Pharmaceutical PreparationsIBA
03/2022 - 04/2016
4Peptides (Polypeptides)IBA
01/2020 - 01/2018
4L-Lactate Dehydrogenase (Lactate Dehydrogenase)IBA
01/2018 - 08/2014
4B-Cell Activating FactorIBA
01/2016 - 05/2013
3AnthracyclinesIBA
09/2022 - 11/2019
3Cyclophosphamide (Cytoxan)FDA LinkGeneric
10/2021 - 09/2015
3Doxorubicin (Adriamycin)FDA LinkGeneric
10/2021 - 08/2014
3PlatinumIBA
01/2020 - 08/2015
3Interleukin-8 (Interleukin 8)IBA
01/2018 - 01/2017
3IfosfamideFDA LinkGeneric
09/2015 - 07/2015
2Anaplastic Lymphoma KinaseIBA
07/2022 - 02/2015
2Vincristine (Oncovin)FDA LinkGeneric
10/2021 - 09/2015
2GoldIBA
08/2021 - 01/2020
2RutheniumIBA
08/2021 - 04/2021
2Biomarkers (Surrogate Marker)IBA
12/2020 - 01/2019
2ParaffinIBA
01/2019 - 08/2012
2Formaldehyde (Formol)FDA Link
01/2019 - 08/2012
2AcidsIBA
01/2019 - 02/2017
2Antineoplastic Agents (Antineoplastics)IBA
01/2018 - 01/2017
2imidazo(1,2-a)quinoxaline-2-carboxylic acidIBA
01/2018 - 02/2017
2Aspirin (Acetylsalicylic Acid)FDA LinkGeneric
01/2018 - 09/2017
2Etoposide (VP 16)FDA LinkGeneric
10/2017 - 09/2015
2PyransIBA
09/2017 - 01/2017
2Carboxylic AcidsIBA
09/2017 - 01/2017
2Oxaliplatin (Eloxatin)FDA LinkGeneric
02/2014 - 07/2009
2Calcium-Calmodulin-Dependent Protein Kinase Type 2IBA
01/2014 - 05/2013
2Topotecan (Hycamtin)FDA LinkGeneric
10/2013 - 03/2013
1Asparaginase (Elspar)FDA Link
09/2022
1Fluorescein-5-isothiocyanate (FITC)IBA
05/2022
1Metal-Organic FrameworksIBA
03/2022
1Indocyanine Green (Cardio-Green)FDA LinkGeneric
03/2022
1Fluorouracil (Carac)FDA LinkGeneric
03/2022
1Zoledronic Acid (Zometa)FDA Link
03/2022
1Prednisone (Sone)FDA LinkGeneric
10/2021
1Histone Deacetylases (Histone Deacetylase)IBA
10/2021
1N- (2- amino- 5- fluorobenzyl)- 4- (N- (pyridine- 3- acrylyl)aminomethyl)benzamideIBA
10/2021
1Thrombopoietin (c-mpl Ligand)IBA
09/2021
1Liposomes (Liposome)IBA
08/2021
1Transferrin Receptors (Transferrin Receptor)IBA
04/2021
1Transferrin (beta 2 Transferrin)IBA
04/2021
1Cyclin-Dependent Kinase 4IBA
04/2021
1dalpiciclibIBA
04/2021
1anlotinibIBA
01/2021
1sintilimabIBA
01/2021
1Hemoglobins (Hemoglobin)IBA
12/2020
1GlobulinsIBA
12/2020
1AlbuminsIBA
12/2020
1Blood Coagulation Factors (Coagulation Factor)IBA
06/2020
1Protein-Arginine DeiminasesIBA
01/2020

Therapy/Procedure

20Drug Therapy (Chemotherapy)
04/2022 - 10/2009
9Therapeutics
09/2022 - 01/2005
4Radiotherapy
11/2019 - 09/2015
3Stem Cell Transplantation
04/2022 - 01/2014
2Chemoradiotherapy
06/2022 - 01/2021
2Photothermal Therapy
05/2022 - 03/2022
2Hematopoietic Stem Cell Transplantation
10/2017 - 06/2012
1Autologous Transplantation
09/2021
1Immunotherapy
01/2021
1Blood Component Removal (Apheresis)
10/2020
1Platelet Transfusion (Blood Platelet Transfusions)
10/2020